The UIW's Feik School of Pharmacy achieved the highest pharmacy licensure exam pass rate in Texas, while the Class of 2025 ...

NMD Pharma is accelerating ignaseclant’s clinical development in CMT alongside multiple near-term clinical catalysts across its neuromuscular pipeline, with Phase 2 studies in spinal muscular atrophy ...

In a worrying indication of regulatory violations in the medical devices sector, the Drugs Control Administration (DCA), ...

Total net revenue of $15.2 million Adjusted EBITDA1 of $ (0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) ...

BioLife Plasma Services abruptly closed two of its three Wyoming locations Tuesday. Clients, who said they depend on the ...

The Trump administration has launched TrumpRx, a new website designed to steer patients to discounted prescription drugs as health care affordability remains a major concern.

Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 ...

The TrumpRx.gov website helps uninsured & cash-paying patients save on 40+ brand drugs. Here's the complete list of ...

Pharmacy leaders should watch Medicare MFP as it changes Part D drug pricing and introduces new reconciliation challenges for ...

Tuesday afternoon, the House of Representatives voted in favor of a spending bill that includes major pharmacy benefit manager (PBM) reforms aimed at increasing price transparency for consumers and ...

Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...